You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

22-199

Showing 1 - 25 of 3,878
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

B Acute Lymphoblastic Leukemia, Ph-Negative ALL, High Risk Acute Lymphoblastic Leukemia Trial (Azacitidine Injection,

Not yet recruiting
  • B Acute Lymphoblastic Leukemia
  • +2 more
  • Azacitidine Injection
  • +2 more
  • (no location specified)
Oct 15, 2023

B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Recurrent B Acute

Recruiting
  • B Acute Lymphoblastic Leukemia
  • +2 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
Dec 16, 2022

Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic

Active, not recruiting
  • Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 2, 2022

Chronic Lymphocytic Leucemia Trial in Cologne (Bendamustine, GA101, ABT-199)

Active, not recruiting
  • Chronic Lymphocytic Leucemia
  • Cologne, Germany
    German CLL Study Group
Sep 14, 2022

Chronic Lymphoid Leukemia Trial in Germany (Bendamustine, Obinutuzumab, Acalabrutinib)

Active, not recruiting
  • Chronic Lymphoid Leukemia
  • Dresden, Germany
  • +16 more
Nov 8, 2022

Relapsed DLBCL, Refractory DLBCL Trial in Hackensack (ABT-199, Ibrutinib, Rituximab)

Active, not recruiting
  • Relapsed Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Hackensack, New Jersey
    John Theurer Cancer Center at Hackensack University Medical Cent
Oct 7, 2022

Chronic Lymphocytic Leukemia, 17p Deletion, Cancer of the Blood and Bone Marrow Trial in Worldwide (ABT-199 (Main Cohort),

Completed
Has Results
  • Chronic Lymphocytic Leukemia
  • +2 more
  • ABT-199 (Main Cohort)
  • ABT-199 (Safety Expansion Cohort)
  • Tucson, Arizona
  • +47 more
Nov 19, 2021

Relapsed/Refractory Multiple Myeloma Trial in Australia, France, United States (ABT-199, bortezomib, dexamethasone)

Completed
  • Relapsed/Refractory Multiple Myeloma
  • Tucson, Arizona
  • +8 more
Jul 29, 2021

Idiopathic Pulmonary Fibrosis Trial in Birmingham (Venetoclax)

Not yet recruiting
  • Idiopathic Pulmonary Fibrosis
  • Birmingham, Alabama
    A. Brent Carter
Aug 3, 2023

Glioma Trial in United States

Recruiting
  • Glioma
    • Basking Ridge, New Jersey
    • +6 more
    Aug 3, 2022

    Chronic Lymphoid Leukemia Trial in Germany (Bendamustine, Obinutuzumab, Zanubrutinib)

    Recruiting
    • Chronic Lymphoid Leukemia
    • Aachen, Germany
    • +20 more
    Oct 5, 2021

    Relapsed/Refractory Multiple Myeloma Trial in Worldwide (Placebo, Bortezomib, Dexamethasone)

    Completed
    • Relapsed/Refractory Multiple Myeloma
    • Placebo
    • +3 more
    • Aurora, Colorado
    • +96 more
    Aug 22, 2022

    Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia Trial in Australia, United States (ABT-199, Rituximab)

    Completed
    • Small Lymphocytic Lymphoma
    • Chronic Lymphocytic Leukemia
    • La Jolla, California
    • +5 more
    Jul 11, 2022

    Segmentectomy Versus Lobectomy for Lung Adenocarcinoma = 2cm

    Recruiting
    • Lung Adenocarcinoma
    • Lobectomy with systemic lymph node dissection
    • Segmentectomy with systemic lymph node dissection
    • Yangpu, Shanghai, China
      Shanghai Pulmonary Hospital
    Apr 20, 2023

    Stress Urinary Incontinence Trial in Belgium, Germany, United States (Roll-in: AMDC for USR, Placebo, AMDC for USR)

    Completed
    Has Results
    • Stress Urinary Incontinence
    • Placebo
    • Iltamiocel
    • Phoenix, Arizona
    • +28 more
    Dec 12, 2022

    Acute Stroke, Ischemic Stroke, Stroke Trial in United States (Recombinant human tissue kallikrein)

    Active, not recruiting
    • Acute Stroke
    • +2 more
    • Recombinant human tissue kallikrein
    • Fayetteville, Arkansas
    • +14 more
    Jul 27, 2022

    Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Marginal Zone Lymphoma Trial in France (Atezolizumab, Obinutuzumab,

    Completed
    • Follicular Lymphoma
    • +3 more
    • Angers, France
    • +24 more
    Jan 9, 2023

    Lymphoma, Mantle-Cell, Recurrent Lymphoma, Mantle-Cell Trial in United States (ABT-199 and Ibrutinib Combination)

    Completed
    • Lymphoma, Mantle-Cell
    • Recurrent Lymphoma, Mantle-Cell
    • ABT-199 and Ibrutinib Combination
    • Duarte, California
    • +3 more
    May 22, 2022

    Oral Venetoclax Tablets + Subcutaneously Injected Azacitidine in

    Not yet recruiting
    • Acute Myeloid Leukemia
      • (no location specified)
      Sep 22, 2023

      Sickle Cell Anemia Trial in Kingston (Hydroxyurea)

      Recruiting
      • Sickle Cell Anemia
      • Kingston, Jamaica
        Sickle Cell Unit
      Jan 20, 2023

      Periodontitis, Diabetes, Type 2 Trial in Istanbul (Non-Surgical Periodontal Treatment)

      Completed
      • Periodontitis
      • Diabetes Mellitus, Type 2
      • Non-Surgical Periodontal Treatment
      • Istanbul, Turkey
        Marmara University
      Nov 11, 2023

      T-Cell Lymphoma Relapsed, T-Cell Lymphoma Refractory Trial in Italy (Venetoclax)

      Active, not recruiting
      • T-Cell Lymphoma Relapsed
      • T-Cell Lymphoma Refractory
      • Aviano, Italy
      • +12 more
      Dec 20, 2022

      Pregnancy Preterm, Pregnancy Prom, PROM, Preterm (Pregnancy) Trial (Azithromycin Pill, Amoxicillin Pill)

      Not yet recruiting
      • Pregnancy Preterm
      • +5 more
      • Azithromycin Pill
      • Amoxicillin Pill
      • (no location specified)
      Jun 3, 2022

      MUC17-positive Solid Tumors Trial in Worldwide (AMG 199)

      Recruiting
      • MUC17-positive Solid Tumors
      • AMG 199
      • Duarte, California
      • +20 more
      Feb 23, 2022

      Hepatitis B, Chronic Trial in Worldwide (GSK3228836, GSK3528869A, Control)

      Recruiting
      • Hepatitis B, Chronic
      • Edegem, Belgium
      • +47 more
      Jan 24, 2023